Apitegromab in SMA: An Analysis of Additional Efficacy Endpoints in the TOPAZ Study at 36 Months Crawford, T., Darras, B., Day, J., Mercuri, E., Nascimento, A., Mazzone, E., Waugh, A., Song, G., Bilic, S., Marantz, J., Topaz Study Team WILEY. 2023: 192

View details for Web of Science ID 001058307000258